Merck & Co. has announced its third quarter results, projectings its full-year 2023 revenue to be in the range of $59.7 billion to $60.2 billion. That’s roughly in line with the guidance from Pfizer, which recently adjusted its revenue forecast from $58 billion to $61 billion.
As Pfizer deals with reduced demand for COVID-19 products, which helped catapult its overall revenue beyond $100 billion in 2022, Merck saw a surprise Q3 lift from Lagevrio (molnupiravir), whose sales were up 47% to $640 million.
Other top sales drivers include the oncology stalwart Keytruda, which generated $6.3 billion in sales, marking a 17% year-over-year increase. Sales for the HPV vaccine Gardasil/Gardasil 9 amounted to $2.6 billion, reflecting a 13% growth.
Merck Q3 2023 revenue remains robustThe figures keep Merck in the upper echelon of Big Pharmas. In 2022, the company was the second largest with $59.3 billion in overall revenue compared to Pfizer’s $100.3 billion…